

BME – GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 11th November 2022

COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "Facephi" or "the Company", interchangeably).

PRIVILEGED INFORMATION

The Company published as privileged information on the 25th of January 2021 the resolutions adopted by the Extraordinary General Shareholders' Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue warrants convertible into shares of the Company in favour of Nice & Green, S.A. ("Nice & Green"), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase the share capital by the amount necessary to cover the conversion of said warrants.

On November the 10th 2022, under the delegation provided by the Extraordinary General Shareholders' Meeting of the Company held on January 2021, the Board of Directors granted a public deed about the resolution adopted by the Board on November the 7th 2022, about to produce a fourth issuance of 48,076,923 warrants convertible into Company shares for a maximum conversion amount of 2,500,000 euros, the "Equity Warrants NOVEMBER 2022", with Nice & Green being the sole recipient of the issue of the Equity Warrants (NOVEMBER 2022).

Likewise, at the aforementioned General Meeting of January 25, 2021, specifically as set forth in section H - Delegation of Powers, it was agreed to delegate to the board of directors the power to modify, when deemed appropriate, the exercise conditions thereof and their respective term, as well as complete, clarify or modify the other terms and conditions of the Equity Warrants.

Therefore, under that said delegation, in use of the faculties of modification, the Board of Directors has considered as appropriate, to extend the exercise period for the conversion of the Warrants by the recipient, from 64 business days to 365 calendar days.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors